The crosstalk between HER2 signaling and other pathways is complex, affecting cancer progression and treatment resistance.

A new nanozyme-antibody platform selectively targets HER2-positive tumors, disrupting gene expression and reducing metastasis ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible treatment. Their decision is informed by a comprehensive molecular profile ...

A new review was published in Oncotarget, Volume 16, on March 13, 2025, titled "Signaling pathway dysregulation in breast cancer." In this review article, Dinara Ryspayeva and colleagues from ...

A new drug targets RAS-PI3Kα pathways without harmful side effects. It was developed using high-performance computing and AI.

Preliminary results of an observational clinical trial underway at Roswell Park Comprehensive Cancer Center are shedding ...

The latest advancements in upper gastrointestinal (GI) cancer treatment include early detection tools, immunotherapy, ...

It binds to the HER3 receptor on the cancer cells and, together with the HER2 receptor, activates signaling pathways that ensure the growth and survival of the cells.

If you have early-stage HER2-positive breast cancer, here’s good news: There are more treatment options than ever. They can help you live longer while you enjoy a good quality of life.

Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.

Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the potential for improved outcomes.

The FDA has specified use of the Ventana Pathway anti-HER2/neu (4B5) antibody assay. Additionally, the American Society for Clinical Pathology has guidelines for testing for HER2.